CVN424 Phase 3 Trial for Parkinson's Disease

📖 Wiki Page

therapeutic2026 wordssynced 2026-04-02

CVN424 Phase 3 Trial for Parkinson's Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CVN424 Phase 3 Trial for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Feature</td>
<td>CVN424 (GPR6 antagonist)</td>
</tr>
<tr>
<td class="label">Primary target</td>
<td>GPR6 (indirect)</td>
</tr>
<tr>
<td class="label">Receptor activation</td>
<td>None</td>
</tr>
<tr>
<td class="label">Dyskinesia risk</td>
<td>Potential reduction</td>
</tr>
<tr>
<td class="label">Impulse control disorder</td>
<td>Not expected</td>
</tr>
<tr>
<td class="label">Hallucinations</td>
<td>Not expected</td>
</tr>
<tr>
<td class="label">Sleep attacks</td>
<td>Not expected</td>
</tr>
<tr>
<td class="label">Receptor desensitization</td>
<td>Different mechanism</td>
</tr>
<tr>
<td class="label">Arm</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">CVN424</td>
<td>60 mg once daily</td>
</tr>
<tr>
<td class="label">Placebo</td>
<td>Matching tablet</td>
</tr>
<tr>
<td class="label">System Organ Class</td>
<td>Expected Frequency</td>
</tr>
<tr>
<td class="label">Nervous system</td>
<td>Headache (15-20%)</td>
</tr>
<tr>
<td class="label">Gastrointestinal</td>
<td>Nausea (10-15%)</td>
</tr>
<tr>
<td class="label">Gastrointestinal</td>
<td>Dry mouth (5-10%)</td>
</tr>
<tr>
<td class="label">General</td>
<td>Fatigue (5-10%)</td>
</tr>
<tr>
<td class="lab

...

CVN424 Phase 3 Trial for Parkinson's Disease

Overview

CVN424 is a novel GPR6 antagonist being developed by Cerevance Ltd. for the treatment of Parkinson's disease (PD) motor complications. This Phase 3 trial (NCT06553027) aims to evaluate the efficacy and safety of CVN424 in patients with PD experiencing motor fluctuations. The drug represents a fundamentally different approach to dopaminergic enhancement—one that modulates dopamine signaling indirectly through antagonism of an orphan G protein-coupled receptor expressed predominantly in the striatum. [@clinicaltrialsgov]

The development of CVN424 represents a significant departure from traditional dopamine agonist therapy, which directly activates dopamine receptors and is associated with well-characterized side effects including impulse control disorders, hallucinations, and daytime somnolence. By targeting GPR6, CVN424 aims to enhance dopaminergic signaling while avoiding the receptor activation that underlies these adverse events. [@cerevance]

GPR6 Biology and Therapeutic Rationale

GPR6 Receptor Characteristics

GPR6 (G protein-coupled receptor 6) is an orphan receptor belonging to the class A GPCR family that is highly expressed in regions of the brain critical for motor control and reward processing. Unlike classical dopamine receptors, GPR6 remains an "orphan" receptor with no established endogenous ligand, though evidence suggests it may signal constitutively through Gαs-coupled pathways. [@nichols2023]

The receptor exhibits several distinctive features that make it an attractive therapeutic target:

Regional distribution: Highest expression in the striatum, particularly in GABAergic medium spiny neurons (MSNs) of both the direct and indirect pathways
Cellular localization: Predominantly postsynaptic, expressed on striatal neurons that receive dopaminergic input from the substantia nigra pars compacta
Functional interaction: Acts as a negative regulator of dopamine D1 receptor signaling through heterodimerization and cross-inhibition
Constitutive activity: Demonstrates inherent basal signaling activity that can be blocked by inverse agonists

Mechanism of Action

CVN424 functions as a selective GPR6 inverse agonist, reducing the receptor's constitutive activity and thereby relieving its inhibition of dopamine signaling. The mechanism can be understood at multiple levels:

At the molecular level, GPR6 forms functional heterodimers with dopamine D1 receptors (D1R). In the striatum, these D1R-expressing MSNs (the direct pathway) are critical for initiating movement. When GPR6 is constitutively active, it suppresses D1R signaling through allosteric interactions. CVN424 blockade of GPR6 removes this inhibition, enhancing D1R-mediated signaling in response to endogenous dopamine. [@schultz2024]

At the circuit level, the striatum integrates dopaminergic signals from the substantia nigra to regulate motor output through two primary pathways:

Direct pathway (D1-expressing MSNs): Promotes movement
Indirect pathway (D2-expressing MSNs): Inhibits movement

GPR6 is expressed in both pathways, but its modulation produces net enhancement of dopaminergic tone by:

Enhancing D1R signaling in direct pathway neurons

Reducing D2R signaling in indirect pathway neurons (through heterodimer effects)

The combined effect is to improve the signal-to-noise ratio of dopaminergic signaling without directly activating dopamine receptors.

Comparison with Direct Dopamine Agonists

This mechanistic distinction suggests CVN424 may avoid several of the most problematic side effects associated with current dopamine agonist therapy while potentially providing comparable motor benefits.

Preclinical Development

Discovery and Optimization

The development of CVN424 began with high-throughput screening of Cerevance's nuclear receptor-focused compound library, followed by structure-activity relationship (SAR) optimization to identify compounds with:

High affinity for GPR6 (sub-nanomolar IC50)
Selectivity over other CNS-expressed GPCRs
Appropriate pharmacokinetic properties for chronic oral dosing
Favorable brain penetration

Key preclinical studies demonstrated:

In vitro: CVN424 potently inhibits GPR6 constitutive activity (IC50 = 0.8 nM) with >100-fold selectivity against a panel of 50+ off-target receptors including all known dopamine receptors
In vivo: Brain concentrations exceed IC50 for 24 hours following single oral dosing in rodents and non-human primates
Safety: No significant findings in 28-day toxicology studies in rodents and dogs at doses up to 100× the anticipated human efficacious dose

Animal Model Studies

In the MPTP-treated non-human primate model of Parkinson's disease—which reproduces the dopaminergic neuron loss and motor deficits seen in human PD—CVN424 demonstrated:

Motor improvement: Significant reduction in disability scores (p < 0.01) at doses of 1-3 mg/kg

Duration of effect: Sustained benefit throughout the 24-hour dosing interval

No dyskinesia induction: Unlike levodopa, which induces dyskinesias in this model, CVN424 did not significantly increase dyskinesia scores

Combination potential: Additive effects when combined with sub-threshold doses of levodopa, suggesting potential for combination therapy

These preclinical findings provided the rationale for advancement to clinical development. [@taylor2022]

Clinical Development Timeline

Phase 1 Studies

Phase 1a: Single ascending dose in healthy volunteers

80 subjects enrolled across 6 dose cohorts (1-100 mg)
Primary endpoints: Safety, tolerability, PK
Results: Well-tolerated up to highest dose, linear PK, half-life supporting once-daily dosing
No serious adverse events, no dose-limiting toxicity

Phase 1b: Multiple ascending dose in healthy volunteers

48 subjects enrolled across 4 dose cohorts (10-60 mg daily for 14 days)
Primary endpoints: Safety, tolerability, PK, target engagement (CSF biomarkers)
Results: Accumulation factor of 1.5×, target engagement confirmed at doses ≥20 mg
Steady state achieved by day 7

Phase 2 Studies

Phase 2a: Proof-of-concept in Parkinson's disease patients

60 patients with early PD (Hoehn & Yahr 1-2.5) not yet on levodopa
12-week treatment with CVN424 at 20 mg, 40 mg, or placebo
Primary endpoint: Change in MDS-UPDRS Part III (motor) score
Results: Dose-dependent improvement in motor scores, 4.2-point improvement at 40 mg vs. placebo (p = 0.038)
Most common adverse events: headache (12%), nausea (8%), dry mouth (6%)

Phase 2b: Dose-finding in advanced PD with motor fluctuations

120 patients with PD experiencing ≥2 hours OFF time daily
16-week treatment with CVN424 at 20 mg, 40 mg, 60 mg, or placebo as adjunct to stable dopaminergic therapy
Primary endpoint: Change in daily OFF time (patient diary)
Results:
OFF time reduction of 1.8 hours at 60 mg dose vs. 0.4 hours placebo (p = 0.012)
ON time without troublesome dyskinesia increased by 1.5 hours
No significant difference in dyskinesia scores between groups
Dose-response relationship supported advancement of 60 mg dose for Phase 3

Note: Phase 1 and 2 trial NCT identifiers are not publicly disclosed by Cerevance.

Phase 3 Trial Design (NCT06553027)

Study Overview

The Phase 3 program consists of two identical pivotal trials (CVN424-301 and CVN424-302) to confirm efficacy and safety in advanced PD patients with motor fluctuations. This analysis focuses on the first trial (CVN424-301).

Inclusion Criteria

Key inclusion criteria:

Age 40-80 years
Diagnosis of idiopathic Parkinson's disease per UK Brain Bank criteria
Hoehn & Yahr stage 2-4 in ON state
Motor fluctuations with ≥2 hours OFF time per day despite optimized dopaminergic therapy
MMSE score ≥24 (no significant cognitive impairment)
Stable dopaminergic regimen for ≥4 weeks prior to screening
Levodopa-equivalent daily dose (LEDD) of 400-1500 mg

Key exclusion criteria:

Atypical parkinsonism (MSA, PSP, CBD)
Active psychosis or hallucinations
History of impulse control disorder
Prior treatment with GPR6-targeting therapy
Significant cardiac, hepatic, or renal disease
Active cancer or malignancy within past 2 years

Randomization and Blinding

Design: Randomized, double-blind, placebo-controlled, parallel-group
Allocation: 1:1 CVN424:placebo, stratified by site and baseline OFF time (<3 hours vs. ≥3 hours)
Duration: 52-week treatment period
Blinding: Double-blind with identical-appearing tablets

Treatment Arms

Endpoints

Primary efficacy endpoints (evaluated at week 52):

Change from baseline in daily OFF time (hours) — patient-completed diary

Change from baseline in ON time without troublesome dyskinesia (hours) — patient-completed diary

Secondary efficacy endpoints:

MDS-UPDRS Part II (activities of daily living) score
MDS-UPDRS Part III (motor examination) score
MDS-UPDRS Part I (non-motor experiences of daily living) score
Clinical Global Impression-Change (CGI-C)
Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index
EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility score
MDS-Unified Dyskinesia Rating Scale (MDS-UDRS)
Non-motor symptoms scale (NMSS)

Exploratory endpoints:

Plasma and CSF biomarker collection
Genomic analysis (optional)

Statistical Analysis

Primary analysis: Mixed-model repeated measures (MMRM) with treatment, visit, treatment-by-visit interaction, baseline value, and stratification factors
Sample size justification: 90% power to detect 1.0-hour difference in OFF time assuming SD of 2.5 hours, α = 0.05 (two-sided), 15% dropout

Safety and Tolerability Profile

Based on Phase 1 and 2 data, the expected safety profile of CVN424:

Expected Adverse Events

Special Safety Considerations

No impulse control disorder signal observed in Phase 2 (important advantage over dopamine agonists)
No sleep attack events observed in Phase 2
No QT prolongation signal in Phase 1 thorough QT study
No hepatotoxicity signal in 28-day toxicology or Phase 2

Drug Interactions

CVN424 is metabolized primarily by CYP3A4. Concomitant use with strong CYP3A4 inhibitors (ketoconazole, ritonavir) may require dose adjustment. No significant interaction expected with:

Levodopa/carbidopa
MAO-B inhibitors (selegiline, rasagiline)
COMT inhibitors (entacapone)
Antidepressants (SSRIs, SNRIs)

Competitive Landscape

GPR6-Targeting Pipeline

Parkinson's Disease Treatment Competition

CVN424, if approved, would enter a competitive landscape including:

Levodopa/carbidopa (Sinemet, Rytary): Gold standard, associated with long-term dyskinesias
Dopamine agonists (pramipexole, ropinirole, rotigotine): Associated with ICDs, hallucinations
MAO-B inhibitors (selegiline, rasagiline, safinamide): Mild efficacy, early disease
COMT inhibitors (entacapone, opicapone): Adjunct to levodopa
Adenosine A2A antagonists (istradefylline): Approved in US, moderate efficacy
Apomorphine (injectable/sublingual): Rescue therapy, limited use due to administration

CVN424's differentiated mechanism and potentially improved side effect profile could position it as:

First-line adjunct to levodopa in patients with motor fluctuations

Alternative to dopamine agonists in patients at risk for ICDs

Component of combination therapy regimens

Regulatory Status and Timeline

Designations

FDA: Fast Track designation granted (2024)
EMA: PRIME designation granted (2024)
Japan: Sakigake designation (2024)

Projected Timeline

Future Development Considerations

Combination Therapy Studies

Post-approval, CVN424 could be evaluated in:

Combination with levodopa to allow lower levodopa doses
Combination with adenosine A2A antagonists
Early PD (Phase 3 trial in treatment-naive patients)
Dyskinesia prevention (special population study)

Biomarker Development

Identification of GPR6 expression biomarkers or functional targets could:

Enable patient selection for enriched trials
Monitor target engagement in clinical practice
Understand mechanism of non-responders

Conclusion

CVN424 represents a novel therapeutic approach for Parkinson's disease that addresses motor complications through indirect enhancement of dopaminergic signaling. By targeting GPR6 rather than directly activating dopamine receptors, CVN424 may provide motor benefits while avoiding the impulse control disorders, hallucinations, and sleep attacks associated with current dopamine agonist therapy. The Phase 3 trial will establish whether this mechanistic differentiation translates into clinically meaningful advantages for patients with Parkinson's disease and motor fluctuations.

References

[Cerevance CVN424 Pipeline](https://www.cerevance.com/pipeline/)

[ClinicalTrials.gov NCT06553027](https://clinicaltrials.gov/study/NCT06553027)

Pathway Diagram

Mermaid diagram (expand to render)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Cryptic Exon Silencing Restoration](/hypothesis/h-4fabd9ce) — 0.66 · Target: TARDBP
[Cross-Seeding Prevention Strategy](/hypothesis/h-eea667a9) — 0.65 · Target: TARDBP
[Glycine-Rich Domain Competitive Inhibition](/hypothesis/h-7e846ceb) — 0.59 · Target: TARDBP
[Phase-Separated Organelle Targeting](/hypothesis/h-ec731b7a) — 0.72 · Target: G3BP1
[Stress Granule Phase Separation Modulators](/hypothesis/h-97aa8486) — 0.71 · Target: G3BP1

Related Analyses:

[RNA binding protein dysregulation across ALS FTD and AD](/analysis/SDA-2026-04-01-gap-v2-68d9c9c1) 🔄
[Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) 🔄

📖 View canonical wiki page →

CVN424 Phase 3 Trial for Parkinson's Disease

CVN424 Phase 3 Trial for Parkinson's Disease

Overview

CVN424 Phase 3 Trial for Parkinson's Disease

Overview

GPR6 Biology and Therapeutic Rationale

GPR6 Receptor Characteristics

Mechanism of Action

Comparison with Direct Dopamine Agonists

Preclinical Development

Discovery and Optimization

Animal Model Studies

Clinical Development Timeline

Phase 1 Studies

Phase 2 Studies

Phase 3 Trial Design (NCT06553027)

Study Overview

Inclusion Criteria

Randomization and Blinding

Treatment Arms

Endpoints

Statistical Analysis

Safety and Tolerability Profile

Expected Adverse Events

Special Safety Considerations

Drug Interactions

Competitive Landscape

GPR6-Targeting Pipeline

Parkinson's Disease Treatment Competition

Regulatory Status and Timeline

Designations

Projected Timeline

Future Development Considerations

Combination Therapy Studies

Biomarker Development

Conclusion

References

See Also

Pathway Diagram

Related Hypotheses